Chronic Kidney Disease Pipeline Booms as 90+ Therapies Likely to Enter in the Treatment Domain

New York, USA, May 08, 2023 (GLOBE NEWSWIRE) -- Chronic Kidney Disease Pipeline Booms as 90+ Therapies Likely to Enter in the Treatment Domain | DelveInsight

Chronic kidney disease (CKD) is a debilitating condition that affects people all over the world, and it is one of a small number of non-communicable diseases that have shown an increase in associated deaths over the past two decades. Chronic kidney disease is more prevalent in older individuals, women, racial minorities, and people experiencing diabetes mellitus and hypertension. This increasing prevalence is expected to create a favorable environment for novel products to succeed. Companies all across the world have moved their focus to CKD treatment. The rise in incidence will boost the market for CKD treatment.

DelveInsight's 'Chronic Kidney Disease Pipeline Insight 2023' report provides comprehensive global coverage of pipeline chronic kidney disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the chronic kidney disease pipeline domain.

Key Takeaways from the Chronic Kidney Disease Pipeline Report

DelveInsight's chronic kidney disease pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for chronic kidney disease treatment.
Key chronic kidney disease companies such as Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, KBP Biosciences, AstraZeneca, Allena Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, CinCor Pharma, Galapagos NV, Sentien Biotechnologies, Inc., Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Pharmicell, Lisata Therapeutics, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, GNI Group, Algomedix, Maze Therapeutics, Chinook Therapeutics, Angion Biomedica Corp, Arch Biopartners, Scohia Pharma, Algernon Pharmaceuticals, TICEBA GmbH, and others are evaluating new chronic kidney disease drugs to improve the treatment landscape.
Promising chronic kidney disease pipeline therapies such as Empagliflozin, Bardoxolone methyl, Ziltivekimab, KBP-5074, AZD9977, ALLN-346, BI-685509, SCO-792, DM199, Baxdrostat, GLPG2737, SBI-101, REGN5459, ELIXCYTE, FT011, Cellgram-CKD, CLBS201, UNI-494, Research Program, SZ007, Renal progenitor cells, MSCKD, F351, Research programme: TRPC6 antagonist, APOL1 Programme, Research and discovery programs: severe chronic kidney disease, ROCK2 Inhibitor, LSALT peptide, SCO-116, Repirinast, and others are under different phases of chronic kidney disease clinical trials.
In March 2023, POXEL SA, announced the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. For the first time, POXEL SA showed beneficial effects of a direct and selective AMPK activator in preclinical ADPKD models from three species: mouse, human, and dog. These results confirm the potential utility of AMPK activation for this disease and support the development of PXL770 in the Phase 2 clinical program for ADPKD.
In February 2023, AstraZeneca announced the successful completion of the acquisition of CinCor Pharma, Inc. The acquisition bolsters AstraZeneca's cardiorenal pipeline by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio.
In January 2023, the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced.
In November 2022, the Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, which designed, conducted and analyzed EMPA-KIDNEY in a scientific collaboration with Boehringer Ingelheim and Eli Lilly and Company, announced that EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance® (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% vs. placebo (HR; 0.72; 95% CI 0.64 to 0.82; P<0.0001).
In October 2022, Revelation Biosciences Inc. announced positive results in a preclinical model of acute kidney injury (AKI), chronic kidney disease (CKD). Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose-dependent manner in the medium and high dose groups (21.7% reduction (p <0.05) and 29.3% (p < 0.05), respectively) and was comparable to a known TGF-β inhibitor of fibrosis used as a positive control (38.1% reduction (P < 0.05)).
In October 2022, French Biopharma Company Poxel SA announced the U.S. Food and Drug Administration (FDA) had granted orphan drug designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator – and is also a phase 2-ready ADPKD asset, subject to additional financing.

Request a sample and discover the recent advances in chronic kidney disease treatment drugs @ Chronic Kidney Disease Pipeline Report

The chronic kidney disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage chronic kidney disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the chronic kidney disease clinical trial landscape.

Chronic Kidney Disease Overview

Chronic kidney disease occurs when the kidneys are damaged and unable to filter blood. As a result, additional blood fluid and waste linger in the body, potentially contributing to various health problems such as heart disease and stroke. The severity of chronic kidney disease varies. It usually worsens over time, but treatment has been demonstrated to reduce the progression. If chronic kidney disease is not treated, it can lead to renal failure and early cardiovascular disease. Chronic kidney disease is more common in the elderly. In the United States, it is the leading cause of death. It is believed that 37 million US adults have chronic kidney disease, with the majority going undetected. Early-stage kidney disease typically has no symptoms, and many people are unaware they have chronic kidney disease until it is well advanced.

Chronic kidney disease patients may not feel poorly or notice any signs. If kidney disease proceeds slowly, CKD signs and symptoms develop over time. Kidney failure can result in an accumulation of fluid or waste, as well as electrolyte imbalances. Chronic kidney disease symptoms include hypertension, anemia, edoema, weariness, decreased urine output, blood in urine, dark urine, lack of appetite, and persistent itching skin.

Find out more about chronic kidney disease treatment drugs @ Drugs for Chronic Kidney Disease Treatment

A snapshot of the Chronic Kidney Disease Pipeline Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
Empagliflozin	Boehringer Ingelheim/Eli Lilly and Company	Preregistration	Sodium-glucose transporter 2 inhibitors	Oral
Bardoxolone methyl	Reata Pharmaceuticals	Phase III	Cyclo-oxygenase 2 inhibitors; I-kappa B kinase inhibitors; NF E2 related factor 2 stimulants; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; STAT3 transcription factor inhibitors	Oral
KBP-5074	KBP Biosciences	Phase III	Mineralocorticoid receptor antagonists	Oral
Ziltivekimab	Novo Nordisk	Phase III	Interleukin 6 inhibitors	Subcutaneous
US-APR2020	Kibow Pharma	Phase II/III	Bacteria replacements; Microbiome modulators	Oral
DM199	DiaMedica Therapeutics	Phase II	Tissue kallikrein replacements	Subcutaneous
Sucunamostat	SCOHIA PHARMA/Takeda	Phase II	Enteropeptidase inhibitors	Oral
AL-01211	AceLink Therapeutics	Phase I	Glucosylceramide synthase inhibitors	Oral

Learn more about the emerging chronic kidney disease pipeline therapies @ Chronic Kidney Disease Clinical Trials

Chronic Kidney Disease Therapeutics Assessment

The chronic kidney disease pipeline report proffers an integral view of the chronic kidney disease emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Chronic Kidney Disease Pipeline Report

Coverage: Global
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular, Topical
Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
Therapeutics Assessment By Mechanism of Action: Mineralocorticoid receptor antagonists, Interleukin 6 inhibitors, Bacteria replacements, Microbiome modulators, Tissue kallikrein replacements, Glucosylceramide synthase inhibitors, Sodium-glucose transporter 2 inhibitors, Cyclo-oxygenase 2 inhibitors, I-kappa B kinase inhibitors, NF E2 related factor 2 stimulants, NF-kappa B inhibitors, Nitric oxide synthase type II inhibitors, STAT3 transcription factor inhibitors, Enteropeptidase inhibitors
Key Chronic Kidney Disease Companies: Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, KBP Biosciences, AstraZeneca, Allena Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, CinCor Pharma, Galapagos NV, Sentien Biotechnologies, Inc., Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Pharmicell, Lisata Therapeutics, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, GNI Group, Algomedix, Maze Therapeutics, Chinook Therapeutics, Angion Biomedica Corp, Arch Biopartners, Scohia Pharma, Algernon Pharmaceuticals, TICEBA GmbH, and others
Key Chronic Kidney Disease Pipeline Therapies: Empagliflozin, Bardoxolone methyl, Ziltivekimab, KBP-5074, AZD9977, ALLN-346, BI-685509, SCO-792, DM199, Baxdrostat, GLPG2737, SBI-101, REGN5459, ELIXCYTE, FT011, Cellgram-CKD, CLBS201, UNI-494, Research Program, SZ007, Renal progenitor cells, MSCKD, F351, Research programme: TRPC6 antagonist, APOL1 Programme, Research and discovery programs: severe chronic kidney disease, ROCK2 Inhibitor, LSALT peptide, SCO-116, Repirinast, and others

Dive deep into rich insights for new drugs for chronic kidney disease treatment, visit @ Chronic Kidney Disease Drugs

Table of Contents

1.	Chronic Kidney Disease Pipeline Report Introduction
2.	Chronic Kidney Disease Pipeline Report Executive Summary
3.	Chronic Kidney Disease Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Chronic Kidney Disease Clinical Trial Therapeutics
6.	Chronic Kidney Disease Pipeline: Late Stage Products (Pre-registration)
7.	Chronic Kidney Disease Pipeline: Late Stage Products (Phase III)
8.	Chronic Kidney Disease Pipeline: Mid Stage Products (Phase II)
9.	Chronic Kidney Disease Pipeline: Early Stage Products (Phase I)
10.	Chronic Kidney Disease Pipeline Therapeutics Assessment
11.	Inactive Products in the Chronic Kidney Disease Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Chronic Kidney Disease Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the chronic kidney disease pipeline therapeutics, reach out @ Chronic Kidney Disease Treatment Drugs

Chronic Kidney Disease Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted chronic kidney disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic Kidney Disease Market

Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key chronic kidney disease companies, including ProKidney, Reata Pharmaceuticals, Inc., Novo Nordisk A/S, Boehringer Ingelheim, Eli Lilly and Company, KBP Biosciences, Kibow Pharma, Cincor Pharma, among others.

Moderate and Severe Chronic Kidney Disease Market

Moderate and Severe Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate and severe chronic kidney disease companies, including Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Pharmicell, Scohia Pharma, Unicycive Therapeutics, among others.

Moderate and Severe Chronic Kidney Disease Pipeline

Moderate and Severe Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key moderate and severe chronic kidney disease companies, including Kibow Pharma, Bayer, Roche, Caladrius Biosciences, UnicoCell Biomed, Pharmicell, Scohia Pharma, Unicycive Therapeutics, among others.

Anemia In Chronic Kidney Disease Market

Anemia In Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key anemia in chronic kidney disease companies, including Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, among others.

Anemia In Chronic Kidney Disease Pipeline

Anemia In Chronic Kidney Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key anemia in chronic kidney disease companies, including Biocad, Xenetic Biosciences, Chiasma, Liminal BioSciences, among others.

Other Trending Reports

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Connect with us at LinkedIn

Contact Us

Shruti Thakur 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com

Market News and Data brought to you by Benzinga APIs